Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths

被引:18
|
作者
Kropp, Peter A. [1 ]
Bauer, Rosemary [1 ,2 ]
Zafra, Isabella [1 ,3 ]
Graham, Carina [1 ,4 ]
Golden, Andy [1 ]
机构
[1] NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA
[2] Northwestern Univ, Driskill Grad Program, Chicago, IL 60611 USA
[3] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[4] UCL, Inst Child Hlth, London, England
关键词
C; elegans; Disease modeling; Drug screens; Genetic screens; Patient-specific alleles; SPINAL MUSCULAR-ATROPHY; SURVIVAL-MOTOR-NEURON; KSR-1 GENE ENCODES; C-ELEGANS; PLASTIN; PROTEIN; MUTATIONS; NALCN; TOXICITY; CHANNEL;
D O I
10.1242/dmm.049010
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Although nearly 10% of Americans suffer from a rare disease, clinical progress in individual rare diseases is severely compromised by lack of attention and research resources compared to common diseases. It is thus imperative to investigate these diseases at their most basic level to build a foundation and provide the opportunity for understanding their mechanisms and phenotypes, as well as potential treatments. One strategy for effectively and efficiently studying rare diseases is using genetically tractable organisms to model the disease and learn about the essential cellular processes affected. Beyond investigating dysfunctional cellular processes, modeling rare diseases in simple organisms presents the opportunity to screen for pharmacological or genetic factors capable of ameliorating disease phenotypes. Among the small model organisms that excel in rare disease modeling is the nematode Caenorhabditis elegans. With a staggering breadth of research tools, C. elegans provides an ideal system in which to study human disease. Molecular and cellular processes can be easily elucidated, assayed and altered in ways that can be directly translated to humans. When paired with other model organisms and collaborative efforts with clinicians, the power of these C. elegans studies cannot be overstated. This Review highlights studies that have used C. elegans in diverse ways to understand rare diseases and aid in the development of treatments. With continuing and advancing technologies, the capabilities of this small round worm will continue to yield meaningful and clinically relevant information for human health.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Caenorhabditis elegans for preclinical drug discovery
    Arya, Upasna
    Das, Chinmaya Kumar
    Subramaniam, Jamuna R.
    [J]. CURRENT SCIENCE, 2010, 99 (12): : 1669 - 1680
  • [2] Using Caenorhabditis elegans for antimicrobial drug discovery
    Desalermos, Athanasios
    Muhammed, Maged
    Glavis-Bloom, Justin
    Mylonakis, Eleftherios
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2011, 6 (06) : 645 - 652
  • [3] Drug discovery: Insights from the invertebrate Caenorhabditis elegans
    Giunti, Sebastian
    Andersen, Natalia
    Rayes, Diego
    Jose De Rosa, Maria
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (02):
  • [4] Is Caenorhabditis elegans the Magic Bullet for Anthelminthic Drug Discovery?
    Keiser, Jennifer
    [J]. TRENDS IN PARASITOLOGY, 2015, 31 (10) : 455 - 456
  • [5] Caenorhabditis elegans in Parkinson's Disease Drug Discovery: Addressing an Unmet Medical Need
    Nass, Richard
    Merchant, Kalpana M.
    Ryan, Timothy
    [J]. MOLECULAR INTERVENTIONS, 2008, 8 (06) : 284 - 293
  • [6] Drug discovery technologies: Caenorhabditis elegans as a model for anthelmintic therapeutics
    Sepulveda-Crespo, Daniel
    Reguera, Rosa M.
    Rojo-Vazquez, Francisco
    Balana-Fouce, Rafael
    Martinez-Valladares, Maria
    [J]. MEDICINAL RESEARCH REVIEWS, 2020, 40 (05) : 1715 - 1753
  • [7] Modeling Alzheimer's Disease in Caenorhabditis elegans
    Alvarez, Javier
    Alvarez-Illera, Pilar
    Santo-Domingo, Jaime
    Fonteriz, Rosalba I.
    Montero, Mayte
    [J]. BIOMEDICINES, 2022, 10 (02)
  • [8] Caenorhabditis elegans-based Model Systems for Antifungal Drug Discovery
    Anastassopoulou, Cleo G.
    Fuchs, Beth Burgwyn
    Mylonakis, Eleftherios
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (13) : 1225 - 1233
  • [9] A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in Caenorhabditis elegans
    Gorgon, Szymon
    Billing, Ola
    Eriksson, Anna U.
    Hemmingsson, Oskar
    [J]. CANCER RESEARCH COMMUNICATIONS, 2024, 4 (09): : 2454 - 2462
  • [10] Genetic and Pharmacological Discovery for Alzheimer's Disease Using Caenorhabditis elegans
    Griffin, Edward F.
    Caldwell, Kim A.
    Caldwell, Guy A.
    [J]. ACS CHEMICAL NEUROSCIENCE, 2017, 8 (12): : 2596 - 2606